Ask AI
ProCE Banner Activity

CE

CDK4/6 Inhibitors in Breast Cancer: An Oncology Nurse’s Toolkit to Enhance Tolerability and Preserve Benefit

Video

In this certified on-demand webcast, an expert discusses the role of oncology nurses in managing breast cancer with CDK4/6 inhibitors, covering clinical trial evidence, treatment selection, adverse event monitoring and management, and strategies to improve patient adherence. 

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: August 15, 2025

Expiration: August 14, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Target Audience

This activity has been designed to meet the educational needs of nurse practitioners, oncology nurses, and other healthcare professionals who care for patients with breast cancer. 

Program Learning Goal

This activity aims to improve learners’ knowledge and competence in the nursing management of patients with breast cancer who are receiving or eligible for CDK4/6 inhibitor treatment.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Effectively monitor and manage toxicities associated with CDK4/6 inhibitor therapy for patients with HR+/HER2- breast cancer

  • Implement recommended strategies to improve adherence to oral CDK4/6 inhibitor therapy in patients with HR+/HER2- breast cancer

  • Employ effective techniques to mitigate factors leading to early discontinuation of oral anticancer therapy in patients with HR+/HER2- breast cancer

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Sara Cooper, MSN, AOCNP: consultant/advisor/speaker: Accellapy, AstraZeneca, Lilly, Novartis, Stemline.

Ashley Martinez, DNP, APRN, FNP-BC, AOCNP, CPHQ, NEA-BC, NPD-BC: consultant/advisor/speaker: Biotheranostics, Curio Science, Lilly.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Nicolle Rochino, PharmD, RPh, as noted below.​

Nicolle Rochino, PharmD, RPh: employee (relationship has ended): Novo Nordisk.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 15, 2025, through August 14, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour.

ILNA Recertification Points

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:​

  • Care Continuum (OCN, CBCN, CPHON, AOCNP) - 0.5​
  • Coordination of Care (CBCN) - 0.5​
  • Diagnosis and Staging (CBCN) - 0.5​
  • Nursing Practice (CBCN) - 0.5​
  • Oncology Nursing Practice (OCN) - 0.5
  • ​Psychosocial Dimensions of Care (AOCNP, CPHON, OCN, CBCN) - 0.5
  • Roles of the APRN (AOCNP) - 0.5
  • Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP) - 1.0
  • Treatment (OCN, CBCN, AOCNP, CPHON) - 1.0

 Total Points: 1.0*​

 *Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area.  The total amount of ILNA points claimed may not exceed the total amount of nursing continuing professional development (NCPD) awarded from this course.